All In MedTech

PMA device

Edwards Sapien Transcatheter Heart Valve and Transfemoral and Transapical Accessories

Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed

FDA decisions

10

PMA pathway

Device trials

50

Naming "Edwards Sapien"

MAUDE reports

23,519

Brand "Edwards Sapien", since 2015

PubMed studies

1,155

Mentioning "Edwards Sapien"

AI summary across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.

Product review deck

A slide deck reviewing Edwards Sapien Transcatheter Heart Valve and Transfemoral and Transapical Accessories

About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.

  • Executive summary and key facts
  • Technology
  • Clinical evidence and trials
  • Regulatory history and safety
  • Reimbursement, market and competition
  • Risks, outlook and sources

AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.

FDA decisions

The newest 6 of 10 decisions filed under this name.

3 more FDA decisions with a free account

Older decisions: P100041-S011, P100041-S008, P100041-S002, P100041-S001

Medicare coverage

National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.

How devices get paid for

Clinical trials

Device studies on ClinicalTrials.gov that name "Edwards Sapien", any status and sponsor, newest update first.

Open in Trial Radar
  • Edwards LifesciencesPublic (EW)

    NCT03130777 · 86 participants · Start Aug 22, 2017 · Primary completion Jul 14, 2022

    Device: Edwards Alterra Adaptive Prestent with SAPIEN 3 THV · For: Pulmonary Disease; Transcatheter Pulmonary Valve Replacement (TPVR); Tetralogy of Fallot and 2 more

    Sites: Los Angeles, California; San Francisco, California; Aurora, Colorado · 14 sites in all

  • Erasmus Medical CenterAcademic, hospital or other

    NCT04843072 · 600 participants (planned) · Start May 1, 2021 · Primary completion Jun 1, 2028

    Device: EVOLUT R/PRO/PRO+/FX bioprosthesis; Edwards Sapien S3/Ultra bioprosthesis and 1 more · For: Valve Heart Disease

    Sites: Los Angeles, California; Vienna, Austria; Vancouver, Canada · 14 sites in all

  • ALTERRA Post-Approval StudyActive, not recruiting

    Edwards LifesciencesPublic (EW)

    NCT05378386 · 150 participants · Start May 12, 2022 · Primary completion Sep 25, 2025

    Device: Edwards Alterra Adaptive Prestent with SAPIEN 3 Transcatheter Pulmonary Valve System · For: Pulmonary Valve Insufficiency; Complex Congenital Heart Defect; Tetralogy of Fallot and 2 more

    Sites: Birmingham, Alabama; Little Rock, Arkansas; Los Angeles, California · 24 sites in all

47 more trials with a free account

Adverse event reports (MAUDE)

Reports received since 2015 naming the brand "Edwards Sapien", and for the whole product code for context.

This brand

23,519 reports: 997 malfunction, 20,165 injury, 2,352 death

Whole product code NPT

77,669 reports: 12,243 malfunction, 57,723 injury, 7,693 death

Newest reports for this brand

2 more reports with a free account

All reports in MAUDE Monitor

Recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

Published research

The most relevant PubMed records for "Edwards Sapien"[tiab]. The summary above synthesizes these.

PubMedGoogle ScholarLiterature search

Other devices of this type

Also filed under product code NPT.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.